The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas  

作　　者：Michael Offin Bailey Fitzgerald Marjorie G.Zauderer Deborah Doroshow 

机构地区：[1]Thoracic Oncology Service,Department of Medicine,Memorial Sloan Kettering Cancer Center,Weill Cornell Medical College,New York,NY 10065,USA [2]Division of Hematology and Medical Oncology,Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,New York,NY 10029,USA

出　　处：《Journal of Cancer Metastasis and Treatment》2023年第1期194-209,共16页癌症转移与治疗（英文版）

基　　金：This research was supported in part by the NIH/NCI(P30 CA008748).

摘　　要：Despite our growing understanding of the genomic landscape of diffuse pleural mesotheliomas(DPM),there has been limited success in targeted therapeutic strategies for the disease.This review summarizes attempts to develop targeted therapies in DPM,focusing on the following targets being clinically explored in recent and ongoing clinical trials:vascular endothelial growth factor,mesothelin,BRCA1-associated protein 1,Wilms tumor 1 protein,NF2/YAP/TAZ,CDKN2,methylthioadenosine phosphorylase,v-domain Ig suppressor T-cell activation,and argininosuccinate synthetase 1.Although preclinical data for these targets are promising,few have efficaciously translated to benefit our patients.Future efforts should seek to expand the availability of preclinical models that faithfully recapitulate DPM biology,develop clinically relevant biomarkers,and refine patient selection criteria for clinical trials.

关 键 词：MESOTHELIOMA targeted therapy biomarkers GENOMICS 

分 类 号：R734.3[医药卫生—肿瘤]